Henry Schein, Inc. (NASDAQ:HSIC – Free Report) – Equities researchers at Leerink Partnrs boosted their FY2024 earnings per share estimates for Henry Schein in a research report issued on Tuesday, November 5th. Leerink Partnrs analyst M. Cherny now forecasts that the company will earn $4.81 per share for the year, up from their prior estimate of $4.76. The consensus estimate for Henry Schein’s current full-year earnings is $4.74 per share. Leerink Partnrs also issued estimates for Henry Schein’s Q4 2024 earnings at $1.26 EPS, Q1 2025 earnings at $1.18 EPS, Q2 2025 earnings at $1.26 EPS, Q3 2025 earnings at $1.30 EPS and Q4 2025 earnings at $1.45 EPS.
Henry Schein (NASDAQ:HSIC – Get Free Report) last released its quarterly earnings results on Tuesday, November 5th. The company reported $1.22 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.16 by $0.06. Henry Schein had a return on equity of 13.19% and a net margin of 2.82%. The business had revenue of $3.17 billion during the quarter, compared to the consensus estimate of $3.24 billion. During the same period in the previous year, the company posted $1.32 EPS. The business’s quarterly revenue was up .4% compared to the same quarter last year.
Check Out Our Latest Stock Report on Henry Schein
Henry Schein Stock Up 1.5 %
Shares of HSIC stock opened at $70.01 on Thursday. The company has a 50 day simple moving average of $70.59 and a two-hundred day simple moving average of $69.78. The stock has a market cap of $8.87 billion, a P/E ratio of 25.93, a P/E/G ratio of 2.08 and a beta of 0.87. Henry Schein has a 12 month low of $62.05 and a 12 month high of $82.63. The company has a current ratio of 1.55, a quick ratio of 0.90 and a debt-to-equity ratio of 0.46.
Hedge Funds Weigh In On Henry Schein
A number of institutional investors and hedge funds have recently made changes to their positions in HSIC. Empirical Finance LLC grew its position in Henry Schein by 3.5% in the first quarter. Empirical Finance LLC now owns 4,764 shares of the company’s stock worth $360,000 after acquiring an additional 160 shares in the last quarter. Cromwell Holdings LLC boosted its holdings in shares of Henry Schein by 93.4% in the 3rd quarter. Cromwell Holdings LLC now owns 352 shares of the company’s stock worth $26,000 after purchasing an additional 170 shares during the period. Covestor Ltd increased its position in shares of Henry Schein by 12.8% during the 1st quarter. Covestor Ltd now owns 1,511 shares of the company’s stock valued at $114,000 after purchasing an additional 171 shares during the last quarter. Simplify Asset Management Inc. raised its holdings in Henry Schein by 5.0% during the 2nd quarter. Simplify Asset Management Inc. now owns 3,695 shares of the company’s stock valued at $237,000 after buying an additional 175 shares during the period. Finally, Sequoia Financial Advisors LLC lifted its position in Henry Schein by 3.2% in the second quarter. Sequoia Financial Advisors LLC now owns 5,680 shares of the company’s stock worth $364,000 after buying an additional 176 shares during the last quarter. 96.62% of the stock is owned by hedge funds and other institutional investors.
Insiders Place Their Bets
In related news, SVP Lorelei Mcglynn sold 21,035 shares of the firm’s stock in a transaction on Friday, September 6th. The shares were sold at an average price of $69.30, for a total value of $1,457,725.50. Following the completion of the transaction, the senior vice president now directly owns 71,833 shares of the company’s stock, valued at approximately $4,978,026.90. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Corporate insiders own 1.14% of the company’s stock.
Henry Schein Company Profile
Henry Schein, Inc provides health care products and services to dental practitioners, laboratories, physician practices, and ambulatory surgery centers, government, institutional health care clinics, and other alternate care clinics worldwide. It operates through two segments, Health Care Distribution, and Technology and Value-Added Services.
Featured Articles
- Five stocks we like better than Henry Schein
- Most Volatile Stocks, What Investors Need to Know
- What a Trump Win Looks Like for the Market Now and Into 2025
- Biggest Stock Losers – Today’s Biggest Percentage Decliners
- Russell 2000 Surge Post-Election: How to Play the Small-Cap Pop
- What Are the U.K. Market Holidays? How to Invest and Trade
- Macro Headwinds Send Microchip Technology Stock to the Buy Zone
Receive News & Ratings for Henry Schein Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Henry Schein and related companies with MarketBeat.com's FREE daily email newsletter.